Rola miRNA w rozwoju wybranych nowotworów – potencjalne zastosowanie w diagnostyce*
References
- Amr K.S., Ezzat W.M., Elhosary Y.A., Hegazy A.E., Fahim H.H., Kamel R.R.: The potential role of miRNAs 21 and 199-a in early diagnosis of hepatocellular carcinoma. Gene, 2016; 575: 66–70
- Anfossi S., Giordano A., Gao H., Cohen E.N., Tin S., Wu Q., Garza R.J., Debeb B.G., Alvarez R.H., Valero V., Hortobagyi G.N., Calin G.A., Ueno N.T., Woodward W.A., Reuben J.M.: High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer. PLoS One, 2014; 9: e83113
- Antolin S., Calvo L., Blanco-Calvo M., Santiago M.P., Lorenzo-Patiño M.J., Haz-Conde M., Santamarina I., Figueroa A., Antón-Aparicio L.M., Valladares-Ayerbes M.: Circulating miR-200c and miR-141 and outcomes in patients with breast cancer. BMC Cancer, 2015; 15: 297
- Asaga S., Kuo C., Nguyen T., Terpenning M., Giuliano A.E., Hoon D.S.: Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin. Chem., 2011; 57: 84–91
- Basati G., Emami Razavi A., Abdi S., Mirzaei A.: Elevated level of microRNA-21 in the serum of patients with colorectal cancer. Med. Oncol., 2014; 31: 205
- Basati G., Razavi A.E., Pakzad I., Malayeri F.A.: Circulating levels of the miRNAs, miR-194, and miR-29b, as clinically useful biomarkers for colorectal cancer. Tumour Biol., 2016; 37: 1781–1788
- Beckett E.L., Martin C., Choi J.H., King K., Niblett S., Boyd L., Duesing K., Yates Z., Veysey M., Lucock M.: Folate status, folate-related genes and serum miR-21 expression: Implications for miR-21 as a biomarker. BBA Clin., 2015; 4: 45–51
- Branch A.D., Rice C.M.: Antisense gets a grip on miR-122 in chimpanzees. Sci. Transl. Med., 2010; 2: 13ps1
- Cazzoli R., Buttitta F., Di Nicola M., Malatesta S., Marchetti A., Rom W.N., Pass H.I.: microRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer. J. Thorac. Oncol., 2013; 8: 1156–1162
- Chen L., Heikkinen L., Wang C., Yang Y., Sun H., Wong G.: Trends in the development of miRNA bioinformatics tools. Brief. Bioinform., 2019; 20: 1836–1852
- Chen W.Y., Zhao X.J., Yu Z.F., Hu F.L., Liu Y.P., Cui B.B., Dong X.S., Zhao Y.S.: The potential of plasma miRNAs for diagnosis and risk estimation of colorectal cancer. Int. J. Clin. Exp. Pathol., 2015; 8: 7092–7101
- Chen Y., Du M., Wang J., Xing P., Zhang Y., Li F., Lu X.: MiRNA-200a expression is inverse correlation with hepatocyte growth factor expression in stromal fibroblasts and its high expression predicts a good prognosis in patients with non-small cell lung cancer. Onco-target, 2016; 7: 48432–48442
- Conev N.V., Donev I.S., Konsoulova-Kirova A.A., Chervenkov T.G., Kashlov J.K., Ivanov K.D.: Serum expression levels of miR-17, miR-21, and miR-92 as potential biomarkers for recurrence after adjuvant chemotherapy in colon cancer patients. BioSci. Trends, 2015; 9: 393–401
- Cui E.H., Li H.J., Hua F., Wang B., Mao W., Feng X.R., Li J.Y., Wang X.: Serum microRNA 125b as a diagnostic or prognostic biomarker for advanced NSCLC patients receiving cisplatin-based chemotherapy. Acta Pharmacol. Sin., 2013; 34: 309–313
- Del Vescovo V., Grasso M., Barbareschi M., Denti M.A.: MicroRNAs as lung cancer biomarkers. World J. Clin. Oncol., 2014; 54: 604–620
- Dou H., Wang Y., Su G., Zhao S.: Decreased plasma let-7c and miR-152 as noninvasive biomarker for non-small-cell lung cancer. Int. J. Clin. Exp. Med., 2015; 8: 9291–9298
- Ebrahimi A., Sadroddiny E.: MicroRNAs in lung diseases: Recent findings and their pathophysiological implications. Pulm. Pharmacol. Ther., 2015; 34: 55–63
- Eichelser C., Flesch-Janys D., Chang-Claude J., Pantel K., Schwarzenbach H.: Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression. Clin. Chem., 2013; 59: 1489–1496
- Erbes T., Hirschfeld M., Rücker G., Jaeger M., Boas J., Iborra S., Mayer S., Gitsch G., Stickeler E.: Feasibility of urinary microRNA detection in breast cancer patients and its potential as an innovative non-invasive biomarker. BMC Cancer, 2015; 15: 193
- Eyking A., Reis H., Frank M., Gerken G., Schmid K.W., Cario E.: MiR-205 and MiR-373 are associated with aggressive human mucinous colorectal cancer. PLoS One, 2016; 11: e0156871
- Feng C., Xian Q., Liu S.: Micro RNA-518 inhibits gastric cancer cell growth by inducing apoptosis via targeting MDM2. Biomed. Pharmacother., 2018; 97: 1595–1602
- Ferro A., Peleteiro B., Malvezzi M., Bosetti C., Bertuccio P., Levi F., Negri E., La Vecchia C., Lunet N.: Worldwide trends in gastric cancer mortality (1980–2011), with predictions to 2015, and incidence by subtype. Eur. J. Cancer, 2014; 50: 1330–1344
- Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C.: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature, 1998; 391: 806–811
- Gao F., Chang J., Wang H., Zhang G.: Potential diagnostic value of miR-155 in serum from lung adenocarcinoma patients. Oncol. Rep., 2014; 31: 351–357
- Ge W., Yu D.C., Li Q.G., Chen X., Zhang C.Y., Ding Y.T.: Expression of serum miR-16, let-7f, and miR-21 in patients with hepato-cellular carcinoma and their clinical significances. Clin. Lab., 2014; 60: 427–434
- Geng Q., Fan T., Zhang B., Wang W., Xu Y., Hu H.: Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer. Respir. Res., 2014; 15: 149
- Ghanbari R., Mosakhani N., Sarhadi V.K., Armengol G., Nouraee N., Mohammadkhani A., Khorrami S., Arefian E., Paryan M., Malekzadeh R., Knuutila S.: Simultaneous underexpression of let-7a-5p and let-7f-5p microRNAs in plasma and stool samples from early stage colorectal carcinoma. Biomark. Cancer, 2015; 7: 39–48
- Hale M.D., Hayden J.D., Grabsch H.I.: Tumour-microenvironment interactions: Role of tumour stroma and proteins produced by cancer-associated fibroblasts in chemotherapy response. Cell Oncol., 2013; 36: 95–112
- Hanahan D., Weinberg R.A.: Hallmarks of cancer: The next generation, Cell, 2011; 144: 646–674
- Haseeb A., Makki M.S., Khan N.M., Ahmad I., Haqqi T.M.: Deep sequencing and analyses of miRNAs, isomiRs and miRNA induced silencing complex (miRISC)-associated miRNome in primary human chondrocytes. Sci. Rep., 2017; 7: 15178
- Hayes C.N., Chayama K.: MicroRNAs as biomarkers for liver disease and hepatocellular carcinoma. Int. J. Mol. Sci., 2016; 17: 280
- Heegaard N.H., Schetter A.J., Welsh J.A., Yoneda M., Bowman E.D., Harris C.C.: Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer. Int. J. Cancer, 2012; 130: 1378–1386
- Higuchi T., Todaka H., Sugiyama Y., Ono M., Tamaki N., Hatano E., Takezaki Y., Hanazaki K., Miwa T., Lai S., Morisawa K., Tsuda M., Taniguchi T., Sakamoto S.: Suppression of microRNA-7 (miR-7) bio-genesis by nuclear factor 90-nuclear factor 45 complex (NF90-NF45) controls cell proliferation in hepatocellular carcinoma. J. Biol. Chem., 2016; 291: 21074–21084
- Hu Z., Chen X., Zhao Y., Tian T., Jin G., Shu Y., Chen Y., Xu L., Zen K., Zhang C., Shen H.: Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J. Clin. Oncol., 2010; 28: 1721–1726
- Hu Z., Dong J., Wang L.E., Ma H., Liu J., Zhao Y., Tang J., Chen X., Dai J., Wei Q., Zhang C., Shen H.: Serum microRNA profiling and breast cancer risk: The use of miR-484/191 as endogenous controls. Carcinogenesis, 2012; 33: 828–834
- Huang J., Wu J., Li Y., Li X., Yang T., Yang Q., Jiang Y.: Deregulation of serum microRNA expression is associated with cigarette smoking and lung cancer. Biomed. Res. Int., 2014; 2014: 364316
- Huang Z., Huang D., Ni S., Peng Z., Sheng W., Du X.: Plasma micro-RNAs are promising novel biomarkers for early detection of colorectal cancer. Int. J. Cancer, 2010; 127: 118–126
- Janevska D., Chaloska-Ivanova V., Janevski V.: Hepatocellular carcinoma: Risk factors, diagnosis and treatment. Open Access Maced. J. Med. Sci., 2015; 3: 732–736
- Jiang L., Li X., Cheng Q., Zhang B.H.: Plasma microRNA might as a potential biomarker for hepatocellular carcinoma and chronic liver disease screening. Tumour Biol., 2015; 36: 7167–7174
- Jung E.J., Santarpia L., Kim J., Esteva F.J., Moretti E., Buzdar A.U., Di Leo A., Le X.F., Bast R.C., Jr., Park S.T., Pusztai L., Calin G.A.: Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer, 2012; 118: 2603–2614
- Kim J.O., Gazala S., Razzak R., Guo L., Ghosh S., Roa W.H., Bédard E.L.: Non-small cell lung cancer detection using microRNA expression profiling of bronchoalveolar lavage fluid and sputum. Anticancer Res., 2015; 35: 1873–1880
- Kim S.Y., Jeon T.Y., Choi C.I., Kim D.H., Kim D.H., Kim G.H., Ryu D.Y., Lee B.E., Kim H.H.: Validation of circulating miRNA biomarkers for predicting lymph node metastasis in gastric cancer. J. Mol. Diagn, 2013; 15: 661–669
- Kodahl A.R., Lyng M.B., Binder H., Cold S., Gravgaard K., Knoop A.S., Ditzel H.J.: Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: A case control study. Mol. Oncol., 2014; 8: 874–883
- Koga Y., Yamazaki N., Yamamoto Y., Yamamoto S., Saito N., Kakugawa Y., Otake Y., Matsumoto M., Matsumura Y.: Fecal miR-106a is a useful marker for colorectal cancer patients with false-negative results in immunochemical fecal occult blood test. Cancer Epidemiol. Biomarkers Prev., 2013; 22: 1844–1852
- Kogo R., Mimori K., Tanaka F., Komune S., Mori M.: Clinical significance of miR-146a in gastric cancer cases. Clin. Cancer Res., 2011; 17: 4277–4284
- Kumar S., Keerthana R., Pazhanimuthu A., Perumal P.: Over-expression of circulating miRNA-21 and miRNA-146a in plasma samples of breast cancer patients. Indian J. Biochem. Biophys., 2013; 50: 210–214
- Larrea E., Sole C., Manterola L., Goicoechea I., Armesto M., Arestin M., Caffarel M.M., Araujo A.M., Araiz M., Fernandez-Mercado M., Lawrie C.H.: New concepts in cancer biomarkers: Circulating miRNAs in liquid biopsies. Int. J. Mol. Sci, 2016; 17: 627
- Le H.B., Zhu W.Y., Chen D.D., He J.Y., Huang Y.Y., Liu X.G., Zhang Y.K.: Evaluation of dynamic change of serum miR-21 and miR-24 in pre- and post-operative lung carcinoma patients. Med. Oncol., 2012; 29: 3190–3197
- Li J., Liu Y., Wang C., Deng T., Liang H., Wang Y., Huang D., Fan Q., Wang X., Ning T., Liu R., Zhang C.Y., Zen K., Chen X., Ba Y.: Serum miRNA expression profile as a prognostic biomarker of stage II/III colorectal adenocarcinoma. Sci. Rep., 2015; 5: 12921
- Li X.X., Gao S.Y., Wang P.Y., Zhou X., Li Y.J., Yu Y., Yan Y.F., Zhang H.H., Lv C.J., Zhou H.H., Xie S.Y.: Reduced expression levels of let-7c in human breast cancer patients. Oncol. Lett., 2015; 9: 1207–1212
- Lin Q., Chen T., Lin Q., Lin G., Lin J., Chen G., Guo L.: Serum miR-19a expression correlates with worse prognosis of patients with non-small cell lung cancer. J. Surg. Oncol., 2013; 107: 767–771
- Liu F., Wang X., Li J., Gu K., Lv L., Zhang S., Che D., Cao J., Jin S., Yu Y.: miR-34c-3p functions as a tumour suppressor by inhibiting eIF4E expression in non-small cell lung cancer. Cell Prolif., 2015; 48: 582–592
- Liu J., Mao Q., Liu Y., Hao X., Zhang S., Zhang J.: Analysis of miR-205 and miR-155 expression in the blood of breast cancer patients. Chin. J. Cancer Res., 2013; 25: 46–54
- Liu W.J., Xu Q., Sun L.P., Dong Q.G., He C.Y., Yuan Y.: Expression of serum let-7c, let-7i, and let-7f microRNA with its target gene, pepsinogen C, in gastric cancer and precancerous disease. Tumour Biol., 2015; 36: 3337–3343
- Liu X., Feng J., Tang L., Liao L., Xu Q., Zhu S.: The regulation and function of miR-21-FOXO3a-miR-34b/c signaling in breast cancer. Int. J. Mol. Sci., 2015; 16: 3148–3162
- Liu X.G., Zhu W.Y., Huang Y.Y., Ma L.N., Zhou S.Q., Wang Y.K., Zeng F., Zhou J.H., Zhang Y.K.: High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer. Med. Oncol., 2012; 29: 618–626
- Lu J., Zhan Y., Feng J., Luo J., Fan S.: MicroRNAs associated with therapy of non-small cell lung cancer. Int. J. Biol. Sci., 2018; 14: 390–397
- Ma G.J., Gu R.M., Zhu M., Wen X., Li J.T., Zhang Y.Y., Zhang X.M., Chen S.Q.: Plasma post-operative miR-21 expression in the prognosis of gastric cancers. Asian Pac. J. Cancer Prev., 2013; 14: 7551–7554
- Mar-Aguilar F., Mendoza-Ramirez J.A., Malagón-Santiago I., Espino-Silva P.K., Santuario-Facio S.K., Ruiz-Flores P., Rodriguez-Padilla C., Reséndez-Pérez D.: Serum circulating microRNA profiling for identification of potential breast cancer biomarkers. Dis. Markers, 2013; 34: 163–169
- Matamala N., Vargas M.T., Gonzalez-Cámpora R., Miñambres R., Arias J.I., Menéndez P., Andrés-León E., Gómez-López G., Yanowsky K., Calvete-Candenas J., Inglada-Pérez L., Martínez-Delgado B., Benítez J.: Tumor microRNA expression profiling identifies circulating microRNAs for early breast cancer detection. Clin. Chem., 2015; 61: 1098–1106
- Matsumura T., Sugimachi K., Iinuma H., Takahashi Y., Kurashige J., Sawada G., Ueda M., Uchi R., Ueo H., Takano Y., Shinden Y., Eguchi H., Yamamoto H., Doki Y., Mori M. i wsp.: Exosomal microRNA in serum is a novel biomarker of recurrence in human colorectal cancer. Br. J. Cancer, 2015; 113: 275–281
- Mazzoccoli G., Colangelo T., Panza A., Rubino R., Tiberio C., Palumbo O., Carella M., Trombetta D., Gentile A., Tavano F., Valvano M.R., Storlazzi C.T., Macchia G., De Cata A., Bisceglia G. i wsp.: Analysis of clock gene-miRNA correlation networks reveals candidate drivers in colorectal cancer. Oncotarget, 2016; 7: 45444–45461
- Mishra A.K., Yadav P., Mishra A.: A systemic review on staphylococcal scalded skin syndrome (SSSS): A rare and critical disease of neonates. Open Microbiol. J., 2016; 10: 150–159
- Muhammad N., Bhattacharya S., Steele R., Ray R.B.: Anti-miR-203 suppresses ER-positive breast cancer growth and stemness by targeting SOCS3. Oncotarget, 2016; 7: 58595–58605
- Mullick Chowdhury S., Wang T.Y., Bachawal S., Devulapally R., Choe J.W., Abou Elkacem L., Yakub B.K., Wang D.S., Tian L., Paulmurugan R., Willmann J.K.: Ultrasound-guided therapeutic modulation of hepatocellular carcinoma using complementary microRNAs. J. Control Release, 2016; 238: 272–280
- Napoli C., Lemieux C., Jorgensen R.: Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans. Plant Cell, 1990; 2: 279–289
- Ogata-Kawata H., Izumiya M., Kurioka D., Honma Y., Yamada Y., Furuta K., Gunji T., Ohta H., Okamoto H., Sonoda H., Watanabe M., Nakagama H., Yokota J., Kohno T., Tsuchiya N.: Circulating exosomal microRNAs as biomarkers of colon cancer. PLoS One, 2014; 9: e92921
- Okabe H., Satoh S., Furukawa Y., Kato T., Hasegawa S., Nakajima Y., Yamaoka Y., Nakamura Y.: Involvement of PEG10 in human hepatocellular carcinogenesis through interaction with SIAH1. Cancer Res., 2003; 63: 3043–3048
- Peng Y., Zhang X., Ma Q., Yan R., Qin Y., Zhao Y., Cheng Y., Yang M., Wang Q., Feng X., Huang Y., Huang W., Zhao Z., Wang L., Wei Y. i wsp.: MiRNA-194 activates the Wnt/β-catenin signaling pathway in gastric cancer by targeting the negative Wnt regulator, SUFU. Cancer Lett., 2017; 385: 117–127
- Price C., Chen J.: MicroRNAs in cancer biology and therapy: Current status and perspectives. Genes Dis., 2014; 1: 53–63
- Rani S., Gately K., Crown J., O’Byrne K., O’Driscoll L.: Global analysis of serum microRNAs as potential biomarkers for lung adenocarcinoma. Cancer Biol. Ther., 2013; 14: 1104–1112
- Roth C., Kasimir-Bauer S., Pantel K., Schwarzenbach H.: Screening for circulating nucleic acids and caspase activity in the peripheral blood as potential diagnostic tools in lung cancer. Mol. Oncol., 2011; 5: 281–291
- Ru P., Steele R., Hsueh E.C., Ray R.B.: Anti-miR-203 upregulates SOCS3 expression in breast cancer cells and enhances cisplatin chemosensitivity. Genes Cancer, 2011; 2: 720–727
- Salem O., Erdem N., Jung J., Münstermann E., Wörner A., Wilhelm H., Wiemann S., Körner C.: The highly expressed 5′isomiR of hsa-miR-140-3p contributes to the tumor-suppressive effects of miR-140 by reducing breast cancer proliferation and migration. BMC Genomics, 2016; 17: 566
- Sassen S., Miska E.A., Caldas C.: MicroRNA: Implications for cancer. Virchows Arch., 2008; 452: 1–10
- Setoyama T., Ling H., Natsugoe S., Calin G.A.: Non-coding RNAs for medical practice in oncology. Keio J. Med, 2011; 60: 106–113
- Shiotani A., Murao T., Kimura Y., Matsumoto H., Kamada T., Kusunoki H., Inoue K., Uedo N., Iishi H., Haruma K.: Identification of serum miRNAs as novel non-invasive biomarkers for detection of high risk for early gastric cancer. Br. J. Cancer, 2013; 109: 2323–2330
- Shyu Y.C., Lee T.L., Lu M.J., Chen J.R., Chien R.N., Chen H.Y., Lin J.F., Tsou A.P., Chen Y.H., Hsieh C.W., Huang T.S.: miR-122-mediated translational repression of PEG10 and its suppression in human hepatocellular carcinoma. J. Transl. Med., 2016; 14: 200
- Silva J., García V., Zaballos Á., Provencio M., Lombardía L., Almonacid L., García J.M., Domínguez G., Peña C., Diaz R., Herrera M., Varela A., Bonilla F.: Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival. Eur. Respir. J., 2011; 37: 617–623
- Song X., Xin N., Wang W., Zhao C.: Wnt/β-catenin, an oncogenic pathway targeted by H. pylori in gastric carcinogenesis. Oncotarget, 2015; 6: 35579–35588
- Stahlhut Espinosa C.E., Slack F.J.: The role of microRNAs in cancer. Yale J. Biol. Med., 2006; 79: 131–140
- Sun Y., Wang M., Lin G., Sun S., Li X., Qi J., Li J.: Serum micro-RNA-155 as a potential biomarker to track disease in breast cancer. PLoS One, 2012; 7: e47003
- Tagscherer K.E., Fassl A., Sinkovic T., Richter J., Schecher S., Macher-Goeppinger S., Roth W.: MicroRNA-210 induces apoptosis in colorectal cancer via induction of reactive oxygen. Cancer Cell Int., 2016; 16: 42
- Telonis A.G., Loher P., Jing Y., Londin E., Rigoutsos I.: Beyond the one-locus-one-miRNA paradigm: microRNA isoforms enable deeper insights into breast cancer heterogeneity. Nucleic Acids Res., 2015; 43: 9158–9175
- Teplyuk N.M., Mollenhauer B., Gabriely G., Giese A., Kim E., Smolsky M., Kim R.Y., Saria M.G., Pastorino S., Kesari S., Krichevsky A.M.: MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity. Neuro. Oncol., 2012; 14: 689–700
- Toiyama Y., Takahashi M., Hur K., Nagasaka T., Tanaka K., Inoue Y., Kusunoki M., Boland C.R., Goel A.: Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J. Natl. Cancer Inst., 2013; 105: 849–859
- Torre L.A., Bray F., Siegel R.L., Ferlay J., Lortet-Tieulent J., Jemal A.: Global cancer statistics. 2012. CA Cancer J. Clin., 2015; 65: 87–108
- Tsujiura M., Ichikawa D., Komatsu S., Shiozaki A., Takeshita H., Kosuga T., Konishi H., Morimura R., Deguchi K., Fujiwara H., Okamoto K., Otsuji E.: Circulating microRNAs in plasma of patients with gastric cancers. Br. J. Cancer, 2010; 102: 1174–1179
- Tsujiura M., Komatsu S., Ichikawa D., Shiozaki A., Konishi H., Takeshita H., Moriumura R., Nagata H., Kawaguchi T., Hirajima S., Arita T., Fujiwara H., Okamoto K., Otsuji E.: Circulating miR-18a in plasma contributes to cancer detection and monitoring in patients with gastric cancer. Gastric Cancer, 2015; 18: 271–279
- Wang F., Hou J., Jin W., Li J., Yue Y., Jin H., Wang X.: Increased circulating microRNA-155 as a potential biomarker for breast cancer screening: A meta-analysis. Molecules, 2014; 19: 6282–6293
- Wang G., Wang L., Sun S., Wu J., Wang Q.: Quantitative measurement of serum microRNA-21 expression in relation to breast cancer metastasis in Chinese females. Ann. Lab. Med., 2015; 35: 226–232
- Wang H., Hou L., Li A., Duan Y., Gao H., Song X.: Expression of serum exosomal microRNA-21 in human hepatocellular carcinoma. Biomed. Res. Int., 2014; 2014: 864894
- Wang H., Wang L., Wu Z., Sun R., Jin H., Ma J., Liu L., Ling R., Yi J., Wang L., Bian J., Chen J., Li N., Yuan S., Yun J.: Three dysregulated microRNAs in serum as novel biomarkers for gastric cancer screening. Med. Oncol., 2014; 31: 298
- Wang L.G., Gu J.: Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis. Cancer Epidemiol., 2012; 36: e61–e67
- Wang R.J., Zheng Y.H., Wang P., Zhang J.Z.: Serum miR-125a-5p, miR-145 and miR-146a as diagnostic biomarkers in non-small cell lung cancer. Int. J. Clin. Exp. Pathol., 2015; 8: 765–771
- WHO: Cancer Fact Sheets. https://www.who.int/news-room/fact-sheets/detail/cancer (31.10.2018)
- Wu C., Cao Y., He Z., He J., Hu C., Duan H., Jiang J.: Serum levels of miR-19b and miR-146a as prognostic biomarkers for non-small cell lung cancer. Tohoku J. Exp. Med., 2014; 232: 85–95
- Wu H.H., Lin W.C., Tsai K.W.: Advances in molecular biomarkers for gastric cancer: miRNAs as emerging novel cancer markers. Expert Rev. Mol. Med., 2014; 16: e1
- Wu J., Li G., Wang Z., Yao Y., Chen R., Pu X.Y., Wang J.: Circulating microRNA-21 is a potential diagnostic biomarker in gastric cancer. Dis. Markers, 2015; 2015: 435656
- Wu Q., Lu Z., Li H., Lu J., Guo L., Ge Q.: Next-generation sequencing of microRNAs for breast cancer detection. J. Biomed. Biotechnol., 2011; 2011: 597145
- Wu Q., Wang C., Lu Z., Guo L., Ge Q.: Analysis of serum genome-wide microRNAs for breast cancer detection. Clin. Chim. Acta, 2012; 413: 1058–1065
- Wu X., Somlo G., Yu Y., Palomares M.R., Li A.X., Zhou W., Chow A., Yen Y., Rossi J.J., Gao H., Wang J., Yuan Y.C., Frankel P., Li S., Ashing-Giwa K.T. i wsp.: De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer. J. Transl. Med., 2012; 10: 42
- Xiao B., Zhu E.D., Li N., Lu D.S., Li W., Li B.S., Zhao Y.L., Mao X.H., Guo G., Yu P.W., Zou Q.M.: Increased miR-146a in gastric cancer directly targets SMAD4 and is involved in modulating cell proliferation and apoptosis. Oncol. Rep., 2012; 27: 559–566
- Xu L., Li M., Wang M., Yan D., Feng G., An G.: The expression of microRNA-375 in plasma and tissue is matched in human colorectal cancer. BMC Cancer, 2014; 14: 714
- Yang I.P., Tsai H.L., Huang C.W., Huang M.Y., Hou M.F., Juo S.H., Wang J.Y.: The functional significance of microRNA-29c in patients with colorectal cancer: A potential circulating biomarker for predicting early relapse. PLoS One, 2013; 8: e66842
- Yang J.S., Li B.J., Lu H.W., Chen Y., Lu C., Zhu R.X., Liu S.H., Yi Q.T., Li J., Song C.H.: Serum miR-152, miR-148a, miR-148b, and miR-21 as novel biomarkers in non-small cell lung cancer screening. Tumour Biol., 2015; 36: 3035–3042
- Yau T.O., Wu C.W., Dong Y., Tang C.M., Ng S.S., Chan F.K., Sung J.J., Yu J.: microRNA-221 and microRNA-18a identification in stool as potential biomarkers for the non-invasive diagnosis of colorectal carcinoma. Br. J. Cancer, 2014; 111: 1765–1771
- Yau T.O., Wu C.W., Tang C.M., Chen Y., Fang J., Dong Y., Liang Q., Ng S.S., Chan F.K., Sung J.J., Yu J.: MicroRNA-20a in human faeces as a non-invasive biomarker for colorectal cancer. Oncotarget, 2016; 7: 1559–1568
- Yin J., Bai Z., Song J., Yang Y., Wang J., Han W., Zhang J., Meng H., Ma X., Yang Y., Wang T., Li W., Zhang Z.: Differential expression of serum miR-126, miR-141 and miR-21 as novel biomarkers for early detection of liver metastasis in colorectal cancer. Chin. J. Cancer Res., 2014; 26: 95–103
- Yu H., Jiang L., Sun C., Li Guo L., Lin M., Huang J., Zhu L.: Decreased circulating miR-375: A potential biomarker for patients with non-small-cell lung cancer. Gene, 2014; 534: 60–65
- Yuan R., Wang G., Xu Z., Zhao H., Chen H., Han Y., Wang B., Zhou J., Hu H., Guo Z., Shen H., Xue X.: Up-regulated circulating miR-106a by DNA methylation promised a potential diagnostic and prognostic marker for gastric cancer. Anticancer Agents Med. Chem., 2016; 16: 1093–1100
- Yuxia M., Zhennan T., Wei Z.: Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis. J. Cancer Res. Clin. Oncol., 2012; 138: 2045–2050
- Zang H., Wang W., Fan S.: The role of microRNAs in resistance to targeted treatments of non-small cell lung cancer. Cancer Chemother, Pharmacol., 2017; 79: 227–231
- Zeng Q., Jin C., Chen W., Xia F., Wang Q., Fan F., Du J., Guo Y., Lin C., Yang K., Li J., Peng X., Li X., Cao K.: Downregulation of serum miR-17 and miR-106b levels in gastric cancer and benign gastric diseases. Chin. J. Cancer Res., 2014; 26: 711–716
- Zhang J., Song Y., Zhang C., Zhi X., Fu H., Ma Y., Chen Y., Pan F., Wang K., Ni J., Jin W., He X., Su H., Cui D.: Circulating MiR-16-5p and MiR-19b-3p as two novel potential biomarkers to indicate progression of gastric cancer. Theranostics, 2015; 5: 733–745
- Zhang R., Wang W., Li F., Zhang H., Liu J.: MicroRNA-106b~25 expressions in tumor tissues and plasma of patients with gastric cancers. Med. Oncol., 2014; 31: 243
- Zhao W., Zhao J.J., Zhang L., Xu Q.F., Zhao Y.M., Shi X.Y., Xu A.G.: Serum miR-21 level: A potential diagnostic and prognostic biomarker for non-small cell lung cancer. Int. J. Clin. Exp. Med., 2015; 8: 14759–14763
- Zheng R., Pan L., Gao J., Ye X., Chen L., Zhang X., Tang W., Zheng W.: Prognostic value of miR-106b expression in breast cancer patients. J. Surg. Res., 2015; 195: 158–165
- Zhu W., He J., Chen D., Zhang B., Xu L., Ma H., Liu X., Zhang Y., Le H.: Expression of miR-29c, miR-93, and miR-429 as potential biomarkers for detection of early stage non-small lung cancer. PLoS One, 2014; 9: e87780
- Zhuang C., Jiang W., Huang D., Xu L., Yang Q., Zheng L., Wang X., Hu L.: Serum miR-21, miR-26a and miR-101 as potential bio-markers of hepatocellular carcinoma. Clin. Res. Hepatol. Gastroenterol., 2016; 40: 386–396
DOI: https://doi.org/10.5604/01.3001.0014.6578 | Journal eISSN: 1732-2693
Language: English
Page range: 1 - 11
Submitted on: Nov 5, 2019
Accepted on: Aug 20, 2020
Published on: Jan 18, 2021
Published by: Hirszfeld Institute of Immunology and Experimental Therapy
In partnership with: Paradigm Publishing Services
Publication frequency: 1 times per year
Keywords:
Related subjects:
© 2021 Patrycja Paciorek, Mariusz Żuberek, Agnieszka Grzelak, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.